The temporal relationship between urinary c5b-9 and c3dg and clinical parameters in human membranous nephropathy

Nephrology Dialysis Transplantation

Volumn 8, Issue 5, 1993, Pages 397-401

  Coupes, B M ^a   Kon, S P ^a   Brenchley, P E C ^a   Short, C D ^a   Mallick, N P ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Complement activation; Membranous nephropathy; Urinary excretion

Indexed keywords

COMPLEMENT; CREATININE; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LONGITUDINAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; URINALYSIS; URINARY EXCRETION;

COMPLEMENT 3B; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMAN; MALE; MIDDLE AGE; PEPTIDE FRAGMENTS; SUPPORT, NON-U.S. GOV'T;

EID: 0027280320     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a092491     Document Type: Article

References (26)

1. Amaout MA, Rennke HC, Cotran RS. Membranous glomerulonephritis. In: Brenner BM and Stein JH (eds). Contemporary Issues in Nephrology, Churchill Livingstone, New York; 1982: 199-235.
2. Schulze M, Baker PJ, Perkinson DT et al. Increased excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int 1989; 35: 60-68.
3. Pruchno CJ, Burns MM, Schulze M et al. Urinary excretion of the C5b-9 membrane attack complex of complement is a marker of immune disease activity in autologous immune complex disease nephritis. Am J Pathol 1991; 138: 203-211.
4. Brenchley PEC, Coupes BM, Short CD, O'Donoghue D, Ballardie FW, Mallick NPM. Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney lnt 1992; 41: 933-937.
5. Schulze M, Donadio JV, Pruchno CJ et al. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney lnt 1991; 40: 533-538.
6. Ogrodowski JL, Hebert LA, Sedmak D, Cosio FG, Tamerius J, Kolb W. Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney lnt 1991; 40: 1141-1147.
7. Kusunoki Y, Akutsu Y, Itami N et al. Urinary excretion of terminal complement complexes in glomerular disease. Nephron1991; 59: 27-32.
8. Hasunuma Y, Ohi H, Kojima H, Fujita T, Hatano M. Significance of urinary breakdown products of complement, (abstract) Int. Congress Nephrology 1990; 362.
9. Short CD, Solomon LR, Gokal R, Mallick NP. Methylprednisolone therapy in patients with membranous nephropathy and declining renal function. Q J Med 1987; 65: 929-940.
10. Falk RJ, Dalmasso AP, Kim Y et al. Neoantigen of the polymerized ninth component of complement. Characterisation of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 1983; 72: 560-573.
11. Payne CD. Glin System 3.77. Numerical Algorithms Group, Oxford. 1986.
12. Mallick NP, Short CD, Manos J. Clinical membranous nephropathy. Nephron 1983; 34: 209-219.
13. Collaborative study of the adult idiopathic nephrotic syndrome. A controlled study of short term prednisone treatment in adults with membranous nephropathy. N Engl J Med 1979; 301: 1301-1306.
14. Cameron JS, Healy MJR, Adu D. The Medical Research council trial of short-term high-dose alternate-day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. Q J Med 1990; 74: 133-156.
15. Ponticelli C, Zucchelli P, Passerini P. Therapy of idiopathic membranous nephropathy. Springer Seminars in Immunopathol. 1987; 9: 431-440.
16. West ML, Jindal KK, Bear RR, Goldstein MB. A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis. Kidney lnt 1987; 32: 579-584.
17. Mathieson PW, Turner AN, Maidment CGH, Evans DJ, Rees AJ. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 1988; 2: 869-872.
18. Wagoner RD, Stanson AW, Holley K, Winter CS. Renal vein thrombosis in idiopathic membranous glomerulopathy and the nephrotic syndrome. Incidence and significance. Kidney lnt 1983; 23: 368-374.
19. Mallick NP, Short CD. Membranous nephropathy. In: Catto GRD, ed. Glomerulonephritis. Kluwer Academic Publishers, London; 1990: 39-68.
20. Davison AM, Cameron JS, Kerr DNS, Ogg CS, Wilkinson RW. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 1984; 22: 61-67.
21. Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 1985; 312: 1594-1599.
22. Doi T, Kanatsu K, Nagai H, Suehiro F, Kuwahara T, Hamashima Y. Demonstration of C3d deposits in membranous nephropathy. Nephron 1984; 37: 232-235.
23. Coupes BM, Short CD, Brenchley PEC, Boyd S, Mallick NP. Urinary complement breakdown product C3dg in membranous nephropathy; A marker of disease activity? Proc Eur Dial Transplant Assoc 1985; 22: 790-795.
24. Coupes BM, Short CD, O'Donoghue, Ballardie FW, Mallick NP, Brenchley PEC. Urinary MAC and C3dg levels in human membranous nephropathy. Evidence for site of activation and clinical correlation, (abstract) Kidney lnt 1990; 37: 438.
25. Coupes BM, Short CD, Ballardie FW, Mallick NPM, Brenchley PEC. Measurement of urinary complement C5b-9 and C3dg in human membranous nephropathy (HMN). A useful predictor of clinical course, (abstract) JASN 1990; 1: 559.
26. O'Donoghue DJ, Coupes B, Brenchley P, Short C, Ballardie FW. Clinical and autoimmune correlates of complement activation in IgA nephropathy. Int Congress Nephrology (abstract) 1990; 391.